EA201190191A1 - Изотиазоло-пиримидинедионовые производные в качестве модуляторов trpa1 - Google Patents
Изотиазоло-пиримидинедионовые производные в качестве модуляторов trpa1Info
- Publication number
- EA201190191A1 EA201190191A1 EA201190191A EA201190191A EA201190191A1 EA 201190191 A1 EA201190191 A1 EA 201190191A1 EA 201190191 A EA201190191 A EA 201190191A EA 201190191 A EA201190191 A EA 201190191A EA 201190191 A1 EA201190191 A1 EA 201190191A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- trpa1
- isothiazolo
- pyrimidinedione
- modulators
- pyrimidinedione derivatives
- Prior art date
Links
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 title 1
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 title 1
- CBFZADDDBQLSPS-UHFFFAOYSA-N [1,2]thiazolo[4,3-d]pyrimidine 2,2-dioxide Chemical class N1=CN=CC2=NS(=O)(=O)C=C21 CBFZADDDBQLSPS-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 230000001052 transient effect Effects 0.000 abstract 2
- 108060008646 TRPA Proteins 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 abstract 1
- 150000003854 isothiazoles Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN665MU2009 | 2009-03-23 | ||
| US17135509P | 2009-04-21 | 2009-04-21 | |
| PCT/IB2010/000834 WO2010109328A1 (en) | 2009-03-23 | 2010-03-22 | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201190191A1 true EA201190191A1 (ru) | 2012-11-30 |
Family
ID=42236291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201190191A EA201190191A1 (ru) | 2009-03-23 | 2010-03-22 | Изотиазоло-пиримидинедионовые производные в качестве модуляторов trpa1 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8575178B2 (enExample) |
| EP (1) | EP2411397B1 (enExample) |
| JP (1) | JP2012521405A (enExample) |
| KR (1) | KR20120001746A (enExample) |
| CN (1) | CN102395592A (enExample) |
| AP (1) | AP2011005888A0 (enExample) |
| AU (1) | AU2010227224A1 (enExample) |
| BR (1) | BRPI1009372A2 (enExample) |
| CA (1) | CA2756534A1 (enExample) |
| DK (1) | DK2411397T3 (enExample) |
| EA (1) | EA201190191A1 (enExample) |
| ES (1) | ES2424340T3 (enExample) |
| IL (1) | IL215179A0 (enExample) |
| MX (1) | MX2011009821A (enExample) |
| PE (1) | PE20120764A1 (enExample) |
| PL (1) | PL2411397T3 (enExample) |
| PT (1) | PT2411397E (enExample) |
| SG (2) | SG174403A1 (enExample) |
| SI (1) | SI2411397T1 (enExample) |
| UA (1) | UA107342C2 (enExample) |
| WO (1) | WO2010109328A1 (enExample) |
| ZA (1) | ZA201107646B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010227225A1 (en) | 2009-03-23 | 2011-09-15 | Glenmark Pharmaceuticals, S.A. | Furopyrimidinedione derivatives as TRPA1 modulators |
| SG174402A1 (en) | 2009-03-23 | 2011-10-28 | Glenmark Pharmaceuticals Sa | Fused pyrimidine-dione derivatives as trpa1 modulators |
| US8592398B2 (en) | 2010-12-20 | 2013-11-26 | Glenmark Pharmaceuticals, S.A. | 2-amino-4-arylthiazole compounds as TRPA1 antagonists |
| EP2520566A1 (en) | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| RU2014100744A (ru) | 2011-06-13 | 2015-07-20 | Гленмарк Фармасьютикалс С.А. | Лечение респираторных нарушений с помощью trpa1 антагонистов |
| WO2012176105A1 (en) | 2011-06-22 | 2012-12-27 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist |
| JP2014517062A (ja) | 2011-06-22 | 2014-07-17 | グレンマーク ファーマシューティカルズ， エセ．アー． | ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物 |
| WO2013014597A1 (en) | 2011-07-25 | 2013-01-31 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| TWI640519B (zh) * | 2011-11-29 | 2018-11-11 | 泰緯生命科技股份有限公司 | Ｈｅｃ１活性調控因子及其調節方法 |
| JP2015500278A (ja) | 2011-12-05 | 2015-01-05 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔｒｐａ１アンタゴニストと抗コリン剤とを含む医薬組成物 |
| MX354014B (es) | 2012-06-08 | 2018-02-08 | Glenmark Pharmaceuticals Sa | Amidas de compuestos de 2-amino-4-ariltiazol y sus sales. |
| SI2903965T1 (sl) | 2012-10-01 | 2017-07-31 | Orion Corporation | Derivati n-prop-2-inil karboksamida in njihova uporaba kot antagonisti trpa1 |
| CA2884767A1 (en) | 2012-11-14 | 2014-05-22 | Stephan Bachmann | Imidazopyridine derivatives |
| HK1221161A1 (zh) | 2013-06-20 | 2017-05-26 | Glenmark Pharmaceuticals S.A. | 包含trpa1拮抗剂的纳米颗粒制剂 |
| CA2926389A1 (en) | 2013-10-15 | 2015-04-23 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and an analgesic agent |
| WO2015155306A1 (en) * | 2014-04-11 | 2015-10-15 | Almirall, S.A. | New trpa1 antagonists |
| US20190175599A1 (en) | 2014-09-16 | 2019-06-13 | Glemark Pharmaceuticals S.A. | Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain |
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
| WO2018233648A1 (zh) * | 2017-06-21 | 2018-12-27 | 南京明德新药研发股份有限公司 | 作为TLR8激动剂的异噻唑并[4,3-d]嘧啶-5,7-二胺衍生物 |
| CN112794860B (zh) * | 2021-03-24 | 2021-06-29 | 上海肇钰医药科技有限公司 | 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途 |
| CN114656480B (zh) * | 2022-04-27 | 2024-01-26 | 成都施贝康生物医药科技有限公司 | 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2248231A1 (de) * | 1972-10-02 | 1974-04-11 | Basf Ag | 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine |
| SE9701398D0 (sv) | 1997-04-15 | 1997-04-15 | Astra Pharma Prod | Novel compounds |
| ES2193839B1 (es) | 2001-06-22 | 2005-02-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de 6-fenildihidropirrolpirimidindiona. |
| AU2003253165A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| AU2003290066A1 (en) | 2002-12-18 | 2004-07-09 | Novartis Ag | Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons |
| SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
| WO2005077959A1 (en) * | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| US20070196866A1 (en) | 2004-03-13 | 2007-08-23 | Irm Llc | Modulators of ion channel trpa1 |
| US20090062258A1 (en) | 2005-02-03 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
| JP5858557B2 (ja) * | 2005-12-22 | 2016-02-10 | ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． | 疼痛を処置するためのｔｒｐａ１阻害剤 |
| TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| WO2009002933A1 (en) * | 2007-06-22 | 2008-12-31 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
| WO2009158719A2 (en) | 2008-06-27 | 2009-12-30 | Hydra Biosciences, Inc. | Methods and compositions for treating disorders |
-
2010
- 2010-03-22 MX MX2011009821A patent/MX2011009821A/es unknown
- 2010-03-22 WO PCT/IB2010/000834 patent/WO2010109328A1/en not_active Ceased
- 2010-03-22 PE PE2011001703A patent/PE20120764A1/es not_active Application Discontinuation
- 2010-03-22 KR KR1020117023383A patent/KR20120001746A/ko not_active Withdrawn
- 2010-03-22 EP EP10716049.1A patent/EP2411397B1/en not_active Not-in-force
- 2010-03-22 ES ES10716049T patent/ES2424340T3/es active Active
- 2010-03-22 AP AP2011005888A patent/AP2011005888A0/xx unknown
- 2010-03-22 US US13/257,241 patent/US8575178B2/en not_active Expired - Fee Related
- 2010-03-22 SG SG2011066495A patent/SG174403A1/en unknown
- 2010-03-22 EA EA201190191A patent/EA201190191A1/ru unknown
- 2010-03-22 SI SI201030232T patent/SI2411397T1/sl unknown
- 2010-03-22 CA CA2756534A patent/CA2756534A1/en not_active Abandoned
- 2010-03-22 PT PT107160491T patent/PT2411397E/pt unknown
- 2010-03-22 SG SG2012069464A patent/SG184766A1/en unknown
- 2010-03-22 CN CN2010800168801A patent/CN102395592A/zh active Pending
- 2010-03-22 BR BRPI1009372A patent/BRPI1009372A2/pt not_active IP Right Cessation
- 2010-03-22 DK DK10716049.1T patent/DK2411397T3/da active
- 2010-03-22 PL PL10716049T patent/PL2411397T3/pl unknown
- 2010-03-22 JP JP2012501411A patent/JP2012521405A/ja not_active Withdrawn
- 2010-03-22 AU AU2010227224A patent/AU2010227224A1/en not_active Abandoned
- 2010-03-23 UA UAA201111149A patent/UA107342C2/ru unknown
-
2011
- 2011-09-15 IL IL215179A patent/IL215179A0/en unknown
- 2011-10-19 ZA ZA2011/07646A patent/ZA201107646B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG174403A1 (en) | 2011-10-28 |
| PL2411397T3 (pl) | 2013-10-31 |
| JP2012521405A (ja) | 2012-09-13 |
| KR20120001746A (ko) | 2012-01-04 |
| EP2411397B1 (en) | 2013-05-29 |
| PT2411397E (pt) | 2013-06-06 |
| US20120010223A1 (en) | 2012-01-12 |
| HK1166081A1 (en) | 2012-10-19 |
| EP2411397A1 (en) | 2012-02-01 |
| ZA201107646B (en) | 2012-06-25 |
| SI2411397T1 (sl) | 2013-07-31 |
| PE20120764A1 (es) | 2012-06-27 |
| AU2010227224A1 (en) | 2011-09-29 |
| AU2010227224A2 (en) | 2011-10-27 |
| US8575178B2 (en) | 2013-11-05 |
| CA2756534A1 (en) | 2010-09-30 |
| CN102395592A (zh) | 2012-03-28 |
| ES2424340T3 (es) | 2013-10-01 |
| SG184766A1 (en) | 2012-10-30 |
| MX2011009821A (es) | 2012-01-25 |
| AP2011005888A0 (en) | 2011-10-31 |
| IL215179A0 (en) | 2011-12-29 |
| UA107342C2 (en) | 2014-12-25 |
| BRPI1009372A2 (pt) | 2016-05-31 |
| WO2010109328A1 (en) | 2010-09-30 |
| DK2411397T3 (da) | 2013-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201190191A1 (ru) | Изотиазоло-пиримидинедионовые производные в качестве модуляторов trpa1 | |
| EA201190139A1 (ru) | Производные тиенопиримидиндиона в качестве модуляторов trpa1 | |
| EA201390947A1 (ru) | Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1 | |
| EA201190143A1 (ru) | Сочлененные производные пиримидиндионов в качестве модуляторов trpa1 | |
| EA201001371A1 (ru) | Конденсированные пиримидиноновые соединения как модуляторы trpv3 | |
| EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
| EA200900178A1 (ru) | Конденсированные гетероциклические производные и их применение | |
| EA201170705A1 (ru) | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 | |
| EA201170161A1 (ru) | 1,2,5-оксадиазолы в качестве ингибиторов индоламин-2,3-диоксигеназы | |
| WO2009118596A3 (en) | Phthalimide derivatives as trpa1 modulators | |
| EA201190004A1 (ru) | Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3 | |
| EA201070143A1 (ru) | Новые гетероароматические производные и их использование в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов | |
| EA201000642A1 (ru) | 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы | |
| BRPI0608604B8 (pt) | moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica | |
| EA201300471A1 (ru) | Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3 | |
| EA200970065A1 (ru) | Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38 | |
| EA201270339A1 (ru) | Замещенные производные ксантина | |
| ATE430744T1 (de) | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren | |
| MA34094B1 (fr) | Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 | |
| EA201000675A1 (ru) | Производные хромана как модуляторы trpv3 | |
| CY1111128T1 (el) | Στεροειδη παραγωγα 17-φωσφορου χρησιμα ως τροποποιητες υποδοχεων προγεστερονης | |
| CY1113146T1 (el) | 11-φωσφο-στεροειδη παραγωγα ως τροποποιητες του υποδοχεα προγεστερονης | |
| EA201190086A1 (ru) | Сочлененные производные имидазола в качестве антагониста trpv3 | |
| ATE552257T1 (de) | Positive allosterische chinolizidinon-m1- rezeptormodulatoren | |
| EA201290534A1 (ru) | Бициклические тиазолы в качестве аллостерических модуляторов mglur5 рецепторов |